Skip to main content
Premium Trial:

Request an Annual Quote

Microbiologics Licenses Biomatrica Technology for Molecular Controls

NEW YORK (GenomeWeb) – Microbiologics today announced it has licensed Biomatrica's technology for use in its molecular controls for rapid diagnostic instruments and assays.

The deal covers Biomatrica's DNAstable and RNAstable reagents for stabilizing DNA and RNA standards, and combines the firms' biomaterial development expertise and preservation know-how "to create highly stable biological controls that may be globally delivered without cold-chain requirements," the firms said in a statement.

The first Microbiologics product to be stabilized using Biomatrica's technology is the recently launched Helix Elite Molecular Standards, which includes synthetic RNA and DNA sequences as amplification controls in clinical assays.

Microbiologics VP of Molecular Products and Services Brian Beck noted that combining Biomatrica's DNA and RNA stabilizers with Microbiologics' molecular standards improves storage convenience and reliability of the products, leading to lower costs to customers.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.